Mind Medicine (MindMed) Inc.

Good morning, and welcome to the MindMed's first quarter 2025 financial results and corporate update webcast. Currently, all participants are in a listen-only mode. This webcast is live on the Investors and Media section of MindMed's website at mindmed.co, and a replay will be available after the webcast. I would like to introduce Stephanie Fagan, Chief Corporate Affairs Officer of MindMed. Please go ahead.

Thank you, Operator, and good morning, everyone. Thank you for joining us today for a discussion of MindMed's first quarter 2025 business highlights and financial results. Leading the call today will be Rob Barrow, our Chief Executive Officer. He will be joined by Matt Wiley, our Chief Commercial Officer, and Dr. Dan Carlin, our Chief Medical Officer. After our prepared remarks, we will open the call for Q&A. An audio recording and webcast replay for today's conference call will also be available online as detailed in the press release announcement for this call. During today's call, we will be making certain forward-looking statements, including without limitation statements about the potential safety, efficacy, and regulatory and clinical progress of our product candidates, our anticipated cash runway and future expectations, plans, partnerships, and prospects. These statements are subject to various risks, such as changes in market conditions and difficulties associated with research and development and regulatory approval processes. These and other risk factors are described in the filings made with the SEC and the applicable Canadian securities regulators, including our annual report on Form 10-K and our Form 10-Q being filed today. Forward-looking statements are based on the assumptions, opinions, and estimates of management at the date the statements are made. including the non-occurrence of the risks and uncertainties that are described in the filings made with the SEC and the applicable Canadian securities regulators or other significant events occurring outside of MindMed's normal course of business. You are cautioned not to place undue reliance on these forward-looking statements, which are made as of today, May 8, 2025. MindMed disclaims any obligation to update such statements, even if management's views change, except as required by law. With that, let me turn the call over to Rob.

Thank you, Stephanie, and everyone for joining our call today. Before we dive into our business updates and financial results, I want to acknowledge that May is Mental Health Awareness Month, something that is deeply important to us. This is a time to recognize the millions of individuals around the world who are affected by mental health disorders, including Generalized Anxiety Disorder, or GAD, and Major Depressive Disorder, or MDD. At MindMed, our mission to transform the treatment of brain health disorders is closely aligned with the goals of Mental Health Awareness Month. This month, we stand with others working to address the significant challenges faced by those living with mental health conditions. As we continue to advance our clinical programs and deliver on key milestones, we also recognize the vital contributions of the broader community. From the investigators leading our trials to the patients who participate and the many advocates driving awareness and progress, Each plays a crucial role in shaping a future where mental health is treated with the urgency and innovation it deserves. The mental health crisis underscores the need for novel therapies like MM120, our lead program for the potential treatment of GAD and MDD. Three of our pivotal phase three trials evaluating MM120, ODT, and patients with GAD and MDD, Voyage, Panorama, and Emerge, are now actively enrolling And we're seeing strong engagement from clinical sites and patients as momentum continues to build. We're on track to report top line data from Voyage in the first half of 2026 with Panorama and Emerge to follow in the second half. With Breakthrough Therapy designation for MM120 ODT and GAD, a well-defined regulatory strategy, a consistent execution across our programs, we are delivering against our strategic objectives. We believe MM120ODT has the potential to become a differentiated, best-in-class treatment for GAD and MDD, addressing a significant unmet need for over 50 million people in the U.S. alone. Our focus remains on driving this innovation forward and positioning the company for long-term value creation as we move towards commercialization. With three of our pivotal trials now underway and enrollment progressing, We continue to generate evidence to support MM120ODT's potential and highlight its tremendous commercial opportunity. To lead this effort, we recently welcomed our new Chief Commercial Officer, Matt Wiley, to our team. Matt is uniquely positioned to lead our commercial strategy during this critical growth phase. He has more than 25 years of experience having successfully driven the commercialization of innovative therapies with a focus on CNS and psychiatry. He has guided products from development to market launch and accelerated the growth of inline marketed therapies. His expertise and insights bring tremendous value to our team, and we couldn't be more excited about having him on board at such a pivotal time. With that, I'd like to turn the call over to Matt so he can formally introduce himself.